Company: DAWN
Filing Date: 2025-03-06
Form Type: 10-K/A
Source: 0000950170-25-034878
Chunk: 28

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K/A
Chunk 28
---
563 |
| Total short-term investments      |     | $                 | 135,554 |     | $                | 9 |     | $                 | — |     | $                    | 135,563 |

The following table summarizes the maturities of our cash equivalents and available-for-sale securities (in thousands):

|                            |     | December 31, 2024 |         |     |            |         |
|:---------------------------|:----|:------------------|--------:|:----|:-----------|--------:|
|                            |     | Amortized Cost    |         |     | Fair Value |         |
| Mature in one year or less |     | $                 | 511,505 |     | $          | 511,590 |
| Total                      |     | $                 | 511,505 |     | $          | 511,590 |

<div align='center'>F-20</div>

|                            |     | December 31, 2023 |         |     |            |         |
|:---------------------------|:----|:------------------|--------:|:----|:-----------|--------:|
|                            |     | Amortized Cost    |         |     | Fair Value |         |
| Mature in one year or less |     | $                 | 356,404 |     | $          | 356,413 |
| Total                      |     | $                 | 356,404 |     | $          | 356,413 |

The Company regularly reviews the changes to the rating of its securities and monitors the surrounding economic conditions to assess the risk of expected credit losses. As of December 31, 2024 and 2023, there werenosecurities that were in an unrealized loss position for more than 12 months. As of December 31,2024 and 2023, the unrealized losses, if any, on the Company’s short-term investments were primarily caused by interest rate increases. The Company does not expect the issuers to settle any security at a price less than the amortized cost basis of the investment with the contractual cash flows of these investments guaranteed by the issuer. No allowance for credit losses has been recorded since it is not more-likely-than-not that the Company will be required to sell the investments before recovery of their amortized cost basis. Realized gains and losses were immaterial for the year ended December 31, 2024. There werenorealized gains and losses for the year ended December